No description available.

No description available.

Prostasin is expressed in normal prostate epithelial cells but down-regulated in prostate cancers, while prostasin re-expression in invasive prostate cancer cells reduced invasion. We examined prostasin expression and function in benign prostatic hyperplasia (BPH). We evaluated prostasin expression in 12 BPH specimens by immunohistochemistry, and evaluated the impact of prostasin silencing by siRNA on the expression of the inducible nitric oxide synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), and cyclin D1, as well as on cell proliferation and invasion, using the BPH-1 human prostate epithelial cell line model. Prostasin expression was localized in the glands of BPH tissues by immunohistochemistry, in either the tall columnar-shaped or the flattened epithelial cells. We silenced prostasin expression by >50% at both the mRNA and protein levels using siRNA in the BPH-1 human prostate epithelial cell line, and this silencing of prostasin expression was associated with an induction of iNOS and ICAM-1 expression and a down-regulation of cyclin D1 expression. The protein expression of EGFR, a putative prostasin substrate, was not affected by prostasin silencing in this cell line. The prostasin-silenced cells displayed a reduced cell proliferation rate and reduced invasiveness, cell behaviors regulated by cyclin D1, iNOS, and ICAM-1 in the BPH-1 cells. We believe that this down-regulation of cyclin D1 is due to prostasin's augmentative effect on iNOS. We also believe that the decrease in cell motility is due to an increase in iNOS and ICAM-1 as well as a decrease in cyclin D1, since all of these molecules can play a role in cell motility. In conclusion, Prostasin is somehow involved in the regulation of inflammatory gene expression (iNOS and ICAM-1) in prostate epithelial cells, as well as cyclin D1 expression, cell proliferation and invasion, involving molecular mechanisms different than those in the prostate cancer cells. These studies suggest that prostasin is a player in the glandular components of benign prostatic hyperplasia.

No description available.

Prostasin is expressed at the apical surface of normal epithelial cells and suppresses in vitro invasion of cancer cells. Prostasin re-expression in the PC-3 prostate carcinoma cells down-regulated the epidermal growth factor receptor (EGFR) protein expression and EGF-induced phosphorylation of the extracellular signal-regulated kinases (Erk1/2). We report here that prostasin and its activating enzyme matriptase are capable of inducing proteolytic cleavages in the EGFR extracellular domain (ECD) when co-expressed in the FT-293 cells, generating two amino-terminally truncated fragments EGFR135 and EGFR110, at 135 and 110 kDa. Prostasin's role in EGFR cleavage is dependent on the serine active-site but not the GPI-anchor. The modifications of EGFR were confirmed to be on the primary structure by deglycosylation. EGFR135 and EGFR110 are not responsive to EGF stimulation, indicating loss of the ligand-binding domains. EGFR110 is constitutively phosphorylated and in its presence Erk1/2 phosphorylation is increased in the absence of EGF. The protease-induced EGFR cleavages are not dependent on EGFR phosphorylation. The EGFR ECD proteolytic modification by matriptase-prostasin is also observed in the BEAS-2B normal lung epithelial cells, the BPH-1 benign prostate hyperplasia and the MDA-MB-231 breast cancer cell lines; and represents a novel mechanism for epithelial cells to modulate EGF-EGFR signaling.

No description available.

Malaria caused by the protozan parasite Plasmodium is one of the most serious infectious diseases in the developing world. It is estimated that malaria causes an annual mortality rate of ~627,000. New drugs are urgently required, as the incidence of resistance is spreading rapidly. Glycosylphosphatidylinositol (GPI) anchored proteins decorate the merozoite surface and several of which, including merozoite surface proteins - 1 and -2 have previously been shown to be essential for erythrocyte invasion and parasite survival. Plasmodium GPI-anchors contain a glycan core consisting of four mannose residues. Therefore, the enzymes involved in the synthesis of activated mannose, guanidine diphosphomannose pyrophosphorylase (GDP-Man PP) and dolichol phosphate mannose synthase (DPMS), are thought to be crucial for GPI-anchor biosynthesis and as such potential drug targets. Double homologous recombination has been exploited to test whether PfGDP-Man PP and PfDPMS are essential during the erythrocytic portion of the parasite's life cycle. Additionally, overexpression parasite lines for both enzymes have been generated and have shown that the regulation of the two enzymes are intricately linked. Focused metabolomics by multi-reaction monitoring of the overexpression lines suggests that the fucosylation pathway may have a novel function within the parasite, possibly as a dynamic store for activated fucose/mannose. In order to determine the cellular concentration of key metabolites within the parasite, the volumes of the intra-erythrocytic stages have been determined and show that the concentration of metabolites in the ring stage parasites is substantially higher than previously thought. Furthermore, the sub-cellular localisation of GDP-Man PP and DPMS has been determined by immunofluorescence assay. The recombinant expression of DPMS in E. coli allowed its active site residues to be probed as well as establishing a platform for inhibitors to be screened against the enzyme. Finally, inhibitors of the T. brucei DPMS enzyme have been screened against the P. falciparum parasites in culture.

Plasmodium falciparum est responsable de la forme la plus grave de paludisme avec plus de 600 000 décès par an. L'absence de vaccin efficace, combinée à l'émergence de résistances aux traitements récurrents, exige le développement de nouvelles molécules. Afin de limiter ces résistances, il est nécessaire de cibler de nouvelles voies métaboliques indispensables à la survie du parasite. Ce travail de thèse repose sur l'étude de deux voies métaboliques essentielles au parasite que sont la voie de recyclage des bases puriques et la voie de biosynthèse des ancres glycosylphosphatidylinositol (GPI).En ce qui concerne la voie de recyclage des bases puriques, la détermination des structures cristallines de l' « IMP specific 5‘-nucleotidase » (PfISN1) associée aux études biochimiques et biophysiques (SAXS, EM, MALS…), a permis de préciser le mécanisme d'action fournissant ainsi une base solide pour la mise au point d'inhibiteurs. Une banque de plus 3000 composés a été criblée par Fluorimétrie à Balayage Différentiel et les effets des molécules sélectionnées seront évalués sur l'enzyme et sur la croissance du parasite en culture.Quatre cibles thérapeutiques potentielles appartenant à la voie de biosynthèse des ancres GPI ont été sélectionnées. L'utilisation de plusieurs systèmes d'expression disponibles au laboratoire (bactérie, levure, acellulaire en germe de blé) ou via des plateformes européennes pour l‘expression en cellules de mammifères HEK293T (Oxford), de cellules BHK21 transfectées avec le virus de la vaccine modifié, T7-MVA, (Strasbourg) ou la plateforme ESPRIT (Grenoble) ont permis de passer outre les difficultés rencontrées pour exprimer les protéines d'intérêt. L'une des quatre cibles, la mannose-1-phosphate guanylyltransférase (PfMPG), a pu être exprimée de manière suffisante quantitativement et qualitativement pour une caractérisation biochimique et structurale. Une analyse par SAXS et cristallographie aux rayons X a été réalisée / Plasmodium falciparum is responsible for the most severe form of malaria with more than 600,000 deaths per year. The lack of an effective vaccine, combined with the emergence of drug resistant parasites, necessitates the development of new drugs. In order to limit these resistances, it is necessary to target new metabolic pathways essential for parasite survival. This thesis work is based on the study of two metabolic pathways essential to the parasite, the purine salvage pathways and the glycosylphosphatidylinositol (GPI) anchor biosynthesis pathway.Concerning the purine salvage pathway, the determination of the crystal structures of the IMP -specific 5'-nucleotidase (PfISN1) associated with biochemical and biophysical studies (SAXS, EM, MALS, etc.) have allowed to propose a reaction mechanism, thereby providing a solid basis for the conception and development of inhibitors. A library of more than 3000 compounds was screened by Differential Scanning Fluorimetry and the selected molecules will be evaluated for their inhibitory effect on the enzyme and on the growth of parasites in culture.Four potential therapeutic targets belonging to the GPI anchor biosynthesis pathway were selected. The use of several in-house available expression systems (bacteria, yeast, and acellular wheat germ) as well as European platforms for the expression in HEK293T mammalian cells (Oxford), in BHK21 cells transfected with the modified vaccinia virus, T7-MVA, (Strasbourg) or the ESPRIT platform (Grenoble) has allowed us to overcome the difficulties encountered on obtaining the selected protein targets. One of the four targets has been expressed in sufficient amount and quality for biochemical- and structural characterization, namely the mannose-1-phosphate guanylyltransferase (PfMPG). SAXS and X-ray crystallography analyses have been carried out